Masupirdine with Donepezil or Memantine for Dementia BPSD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for behavioral and psychological symptoms of dementia, such as agitation, aggression, delusions, and hallucinations, are inadequate, with existing therapies showing modest efficacy and significant side effects, and there is a need for novel mechanisms that address these symptoms without worsening cognitive function.
Innovation Solution
The combination of masupirdine, a selective 5-HT6 receptor antagonist, with donepezil or memantine, an acetylcholinesterase inhibitor or NMDA antagonist, respectively, to treat agitation, aggression, delusions, and hallucinations in patients with dementia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If atypical antipsychotic agents (risperidone, olanzapine, aripiprazole) are used to treat BPSD, then symptomatic benefit is achieved, but cognitive decline and safety risks increase
Solution Approach 1:
The patent changes the pharmacological parameter by using masupirdine (a 5-HT6 receptor antagonist) instead of atypical antipsychotics, which have different receptor profiles. This parameter change allows treatment of BPSD without the cognitive decline and safety risks associated with antipsychotics, while maintaining symptomatic benefit.
Solution Approach 2:
The patent introduces masupirdine as an intermediary substance that mediates the treatment of BPSD through 5-HT6 receptor antagonism. This intermediary mechanism avoids direct use of harmful antipsychotics while still achieving therapeutic effects, thereby resolving the contradiction between symptom relief and safety.
2Reliability
If donepezil or memantine are used alone, then cognitive function is maintained or improved, but efficacy for severe psychosis and agitation is insufficient
Solution Approach 1:
The patent merges masupirdine with donepezil or memantine in a combination therapy. This combination achieves synergistic effects where masupirdine provides potentiation of cognitive and non-cognitive functions, while donepezil/memantine maintain their cognitive benefits. The merged formulation effectively treats severe psychosis and agitation that neither drug could achieve alone.
3Reliability
If combination therapy with masupirdine and donepezil/memantine is used, then therapeutic efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent positions masupirdine as a multi-functional agent that can be combined with either donepezil or memantine to treat multiple BPSD symptoms. This universal approach allows a single additional drug (masupirdine) to enhance efficacy across different dementia subtypes and symptom profiles, reducing the need for multiple specialized treatments and thereby managing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of masupirdine with donepezil or memantine demonstrates improved therapeutic efficacy in treating a range of behavioral and psychological symptoms in dementia, including reduced aggression and hallucinations, with enhanced neurotransmitter levels in the cortex, indicating potential for better management of neuropsychiatric disorders.
Implementation Method 1
masupirdine, a selective 5-HT6 receptor antagonist
Implementation Method 2
donepezil or memantine, an acetylcholinesterase inhibitor or NMDA antagonist
Implementation Method 3
donepezil or memantine, an acetylcholinesterase inhibitor or NMDA antagonist
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention provides a method for treating behavioral and psychological symptoms in patients with dementia comprising administering an effective dose of pure 5-HT6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist. The present invention also relates to a pharmaceutical combination comprising pure 5-HT6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist, in particular for treating behavioral and psychological symptoms in patients with dementia. The present invention further provides use of the said compounds in the manufacture of a medicament, and a pharmaceutical composition comprising the said compounds intended for the treatment of disorders described herein.